Genetic variation in the EGFR gene and the relation with glioma in Turkish population

While glioma constitutes approximately 30% of brain and central nervous system carcinomas, it covers 80% of all brain carcinomas. [1]. The gene that encodes 170 KD transmembrane receptor tyrosine kinase, located on chromosome 7p12-13 and enounced on the facial of epithelial cells, is the EGFR gene. In most prior works, single nucleotide polymorphisms (SNPs) within the EGFR gene are evaluated to correlate cancer risks like carcinoma, carcinoma, prostatic adenocarcinoma, and esophageal cancer. How EGFR contributes to glioma susceptibility variants in the gene and in order to examine that, in a case-control study from Turkey (35 cases, 36 controls) genotyping both groups determined by real-time PCR and was carried out using statistical analysis SPSS data. According to our results, CC genotype (homozygous wild type) 19 (52.8%), CT genotype (heterozygous type) 16 (44.4%), TT genotype (homozygous variant type) 1 (2.8%) were found in the control group. Genotype distribution in the patient group was 8 (23.5%), 22 (64.7%) and 4 (11.8%), respectively. Significant relationship was found between the patient and control groups compared to genotypes (p = 0.028). This study can provide a new approach to the clinical treatment of glioma patients.